Breaking News Instant updates and real-time market news.

CGC

Canopy Growth

$49.79

2.64 (5.60%)

, CWH

Camping World

$21.37

0.42 (2.00%)

08:45
10/15/18
10/15
08:45
10/15/18
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Canopy Growth (CGC) 8.84% +3.50, Camping World (CWH) 44.85% +2.46, Bluebird Bio (BLUE) 1.41% +1.10, B&G Foods (BGS) 5.39% +0.68, Campbell Soup (CPB) 4.05% +0.62, iShares Transportation Average (IYT) 1.73% +0.34, Nutrien (NTR) 0.59% +0.32, Shire (SHPG) 1.36% +0.19, Geron (GERN) 9.19% +0.12, and Cemex (CX) 0.46% +0.10.

CGC

Canopy Growth

$49.79

2.64 (5.60%)

CWH

Camping World

$21.37

0.42 (2.00%)

BLUE

Bluebird Bio

$125.92

-0.81 (-0.64%)

BGS

B&G Foods

$25.83

-0.16 (-0.62%)

CPB

Campbell Soup

$37.10

-0.05 (-0.13%)

IYT

iShares Transportation Average

$188.69

1.55 (0.83%)

NTR

Nutrien

$54.11

0.05 (0.09%)

SHPG

Acquired by TAK

$170.37

2.14 (1.27%)

GERN

Geron

$1.69

0.02 (1.20%)

CX

Cemex

$6.23

0.145 (2.38%)

  • 22

    Oct

  • 28

    Oct

  • 06

    Nov

  • 13

    Nov

  • 01

    Dec

  • 21

    Dec

CGC Canopy Growth
$49.79

2.64 (5.60%)

10/09/18
COWN
10/09/18
NO CHANGE
Target $172
COWN
Outperform
Tilray price target raised to $172 from $62 at Cowen
Cowen analyst Vivien Azer raised her price target for Tilray (TLRY) to $172 from $62 and keeps an Outperform rating on the shares. The analyst also raised her price target for Outperform-rated Canopy Growth (CGC) to C$82 from C$74.
10/05/18
PIVT
10/05/18
NO CHANGE
Target $300
PIVT
Buy
Constellation Brands price target raised to $300 from $265 at Pivotal Research
Pivotal Research analyst Timothy Ramsey said Constellation Brands reported a "beautiful quarter" and that its core business is "growing faster than anyone believed." In terms of its investment in Canopy Growth (CGC), Ramsey said that is "very likely a masterstroke." He raised his estimates for Constellation on the heels of the report, increased his price target to $300 and keeps a Buy rating on the shares.
10/05/18
MSCO
10/05/18
NO CHANGE
Target $255
MSCO
Overweight
Constellation Brands price target raised to $255 from $251 at Morgan Stanley
Morgan Stanley analyst Dara Mohsenian believes Constellation Brands' (STZ) strong beer fundamentals in Q2 should blunt some investor concerns and continues to think that the market is not appropriately valuing the company's strong long-term growth prospects in beer. The analyst, who also views negative sentiment around the company's investment in cannabis company Canopy Growth (CGC) as overblown, keeps an Overweight rating on Constellation and raised his price target to $255 from $251.
10/12/18
VERI
10/12/18
INITIATION
VERI
Sell
Canopy Growth initiated with a Sell at Veritas
Veritas analyst Stuart Rolfe started coverage of the Canadian Cannabis sector with four Sell ratings, including a Sell on Canopy Growth, in a note entitled "End of the Rainbow." The analyst, who sees an intrinsic value of C$30 for Canopy Growth shares, notes that investors have already driven stock valuations for the eight largest publicly traded Canadian cannabis producers to a combined market cap of $55B on trailing twelve month sales of $250M while "oversupply risks are rampant." Even assuming 60% of the black market converts, Canada's cannabis industry "looks wildly overvalued," Rolfe concludes.
CWH Camping World
$21.37

0.42 (2.00%)

08/15/18
JPMS
08/15/18
NO CHANGE
Target $36
JPMS
Overweight
Camping World price target lowered to $36 from $42 at JPMorgan
JPMorgan analyst Ryan Brinkman reiterated an Overweight rating on Camping World but cut his price target to $36 from $42 to reflect lowered estimates and a lower trading multiple. Although the RV industry is cyclical, Brinkman expects that with the current strong industry backdrop, "solid" M&A activities, earnings will likely outperform over the next several years.
08/17/18
NRCS
08/17/18
NO CHANGE
NRCS
Northcoast says channel checks pointing to weakening RV demand
Northcoast analyst Seth Woolf said he has become incrementally more cautious on the Recreation & Leisure Products group as his channel checks are pointing to weakening retail demand. While he believes "the buy-side is clearly expecting to see weak wholesale numbers in the coming months," Woolf also contends that the magnitude of declines could be a surprise. He maintains a Buy rating on Camping World (CWH) and Neutral ratings on LCI Industries (LCII), Thor Industries (THO) and Winnebago (WGO).
08/21/18
BMOC
08/21/18
NO CHANGE
Target $36
BMOC
Outperform
Camping World price target lowered to $36 from $42 at BMO Capital
BMO Capital analyst Gerrick Johnson lowered his price target on Camping World to $36 but kept his Outperform rating after its Investor Day presentation. The analyst notes that his prior concerns with the Gander Mountain asset purchase have been realized when the company recently cut its EBITDA guidance, however he also sees its change in the retail strategy to be "accretive" next year with solid growth potential going into 2019. Specifically, the analyst is positive on Camping World's plans to use Gander Outdoors as a "back door" to bring its RV dealerships into underpenetrated areas without the capital investment that would be needed at acquired dealerships, adding that the multiple on the stock had previously been negatively impacted by the investors' confusion over the company's plans.
10/11/18
BMOC
10/11/18
NO CHANGE
Target $36
BMOC
Outperform
Camping World is 'significantly undervalued', says BMO Capital
BMO Capital analyst Gerrick Johnson kept his Outperform rating and $36 price target on Camping World, saying its stock is "significantly undervalued" after a 53% year-to-date decline brought its forward earning multiple to 7.5-times. Although the analyst lowers his Q3 EPS view to 60c from 68c to reflect the impact of Hurricane Florence in the Carolinas and Virginia, he also sees the company benefiting from the abating inventory headwinds in the RV industry. Johnson adds that Camping World should start to capture market share and experience cross-selling opportunities after settling on its "Gander RV strategy".
BLUE Bluebird Bio
$125.92

-0.81 (-0.64%)

09/21/18
GSCO
09/21/18
DOWNGRADE
Target $288
GSCO
Buy
Bluebird Bio downgraded to Buy from Conviction Buy at Goldman Sachs
Goldman Sachs analyst Salveen Richter removed Bluebird Bio from his firm's Americas Conviction List but keeps a Buy rating on the name with a $288 price target. The rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats, Richter tells investors in a research note. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels.
09/21/18
09/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bluebird Bio (BLUE) downgraded to Buy from Conviction Buy at Goldman Sachs with analyst Salveen Richter saying rating change is is not driven by concerns around Bluebird's pipeline execution or emerging competitive threats. The analyst just believes appreciation of key aspects of his investment thesis are better reflected in the shares at current valuation levels. 2. Venator Materials (VNTR) downgraded to Neutral from Overweight at JPMorgan with analyst Jeffrey Zekauskas saying he believes lower prices and higher raw material costs for TiO2, coupled with higher capital expenditures, diminishes Venator's free cash flow outlook. 3. Antero Resources (AR) downgraded to Market Perform from Outperform at BMO Capital with analyst Phillip Jungwirth citing valuation. 4. New Age Beverages (NBEV) downgraded to Hold from Buy at Maxim. 5. Rowan Companies (RDC) downgraded to Hold from Buy at HSBC. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
09/17/18
GUGG
09/17/18
INITIATION
Target $164
GUGG
Neutral
Bluebird Bio initiated with a Neutral at Guggenheim
Target $164.
BGS B&G Foods
$25.83

-0.16 (-0.62%)

09/13/18
SPHN
09/13/18
NO CHANGE
Target $35
SPHN
Overweight
Stephens sees B&G Foods trading up after deal to sell Pirate Brands to Hershey
Stephens analyst Farha Aslam said she expects shares of B&G Foods (BGS) to trade up following the announcement of a deal to sell Pirate Brands to Hershey (HSY) for $420M, given the multiple it received and its increased balance sheet flexibility. Pirate Brands is "on-trend," but was not a strong strategic fit for B&G, said Aslam, who reiterated her Overweight rating and $35 price target on the shares. In pre-market trading, B&G Foods shares are up about 2% to $32.60.
06/19/18
06/19/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Ollie's Bargain Outlet (OLLI) initiated with a Hold at Loop Capital. 2. B&G Foods (BGS) assumed with a Neutral at Piper Jaffray. 3. Iterum Therapeutics (ITRM) initiated with an Outperform at RBC Capital and Leerink while being initiated with a Buy at Needham and Guggenheim. 4. Ingersoll-Rand (IR) initiated with an Outperform at Cowen. 5. Ally Financial (ALLY) initiated with a Neutral at Nomura Instinet. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/19/18
PIPR
06/19/18
INITIATION
Target $31
PIPR
Neutral
B&G Foods assumed with a Neutral at Piper Jaffray
Piper Jaffray analyst Michael Lavery assumed coverage of B&G Foods with a Neutral rating and $31 price target. The company's low share positions come with risk of potential distribution losses, Lavery tells investors in a research note. He expects "moderate" earnings growth of 2%-3% over the next few years.
05/04/18
BREN
05/04/18
UPGRADE
BREN
Buy
B&G Foods upgraded to Buy from Hold at Berenberg
CPB Campbell Soup
$37.10

-0.05 (-0.13%)

08/31/18
DBAB
08/31/18
NO CHANGE
Target $36
DBAB
Hold
Campbell Soup price target lowered to $36 from $40 at Deutsche Bank
Deutsche Bank analyst Rob Dickerson lowered his price target for Campbell Soup to $36 saying that while the company topped earnings expectations in Q4, its top line remained pressured, leaving investment needs high. Along with the lack of growth in the Global Biscuits and Snacks division, Americas Simple Meals and Beverages posted a 6% organic sales decline, with soup down 14% and issues at Walmart ongoing, Dickerson tells investors in a post-earnings research note titled "The Eight-Year Giveback." He keeps a Hold rating on Campbell Soup.
08/31/18
FBCO
08/31/18
NO CHANGE
Target $36
FBCO
Underperform
Campbell Soup portfolio simplified, but not enough, says Credit Suisse
After Campbell Soup announced it will divest 20% of its portfolio to de-leverage and refocus on its core businesses in North America, Credit Suisse analyst Robert Moskow said the portfolio simplification plans are not enough. He finds it difficult to embrace the company's new long-term guidance for 7-9% EPS growth and sees "considerable downside risk" to its debt reduction target, Moskow tells investors. He raised his price target on Campbell shares to $36 from $32 to account for a more logical path forward and higher sector multiples, but he keeps an Underperform rating on the stock.
08/31/18
JPMS
08/31/18
NO CHANGE
Target $36
JPMS
Underweight
Campbell's remaining operations face significant challenges, says JPMorgan
JPMorgan analyst Ken Goldman generally agrees with Campbell Soup management that a more focused portfolio will enable better execution and that many cost savings opportunities have yet to be realized. However, But Campbell's remaining operations still face significant challenges, some of which are likely to intensify in the coming year, Goldman tells investors in a research note. He reiterates an Underweight rating on the shares with a year-end 2019 price target of $36.
09/05/18
WOLF
09/05/18
DOWNGRADE
WOLF
Underperform
Campbell Soup downgraded to Underperform from Peer Perform at Wolfe Research
IYT iShares Transportation Average
$188.69

1.55 (0.83%)

NTR Nutrien
$54.11

0.05 (0.09%)

09/20/18
09/20/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Seaspan (SSW) downgraded to Hold from Buy at Deutsche Bank with analyst Amit Mehrotra citing the recent strong performance of the shares and increased risk from the trade war between China and the U.S. 2. Bruker (BRKR) downgraded to Underweight from Equal Weight at Morgan Stanley with analyst Steve Beuchaw citing three company-specific leading indicators that he says point to a slower revenue outlook. 3. Stitch Fix (SFIX) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy citing valuation. 4. Nutrien (NTR) downgraded to Outperform from Focus List at Scotiabank. 5. JD.com (JD) downgraded to Underperform from Outperform at CLSA with the firm lowering its price target to $29 and saying the second half will remain challenging. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/20/18
SCOT
09/20/18
DOWNGRADE
SCOT
Outperform
Nutrien downgraded to Outperform from Focus List at Scotiabank
09/04/18
LEHM
09/04/18
INITIATION
Target $65
LEHM
Overweight
Nutrien initiated with an Overweight at Barclays
Barclays analyst Duffy Fischer started Nutrien with an Overweight rating and $65 price target. The recent rally in fertilizer stocks assumes constructive market conditions will extend beyond the second half of 2018, which is less than certain, Fischer tells investors in a research note. The analyst worries that delayed new capacity is still coming and will stall the price recovery. However, he believes Nutrien has "significant" deal synergies to drive earnings improvement "in spite of the tough macros."
08/29/18
SPHN
08/29/18
NO CHANGE
SPHN
Overweight
India potash contract price suggests tight market, says Stephens
Stephens analyst Mark Connelly noted that India's largest potash importers reportedly signed a new supply contract at a price of $290/mt, which represents a $50/mt increase from the current price and is about $20 higher than his forecast. The direct impact to Nutrien (NTR), Mosaic (MOS) and Intrepid Potash (IPI) is modest given that India volume is relatively small for Canpotex, but the deal suggests a tight potash market and implies that settlement with China is imminent and will be higher, Connelly tells investors. He remains bullish on all three potash stocks mentioned and keeps Overweight ratings on them all.
SHPG Acquired by TAK
$170.37

2.14 (1.27%)

09/07/18
BREN
09/07/18
DOWNGRADE
BREN
Hold
Shire downgraded to Hold from Buy at Berenberg
Berenberg analyst Klara Fernandes downgraded Shire (SHPG) to Hold saying the current valuation offers limited potential upside ahead of the pending takeover by Takeda Pharmaceutical (TKPYY).
09/04/18
09/04/18
DOWNGRADE

Market Perform
Shire downgraded to Market Perform as spread narrows at Bernstein
As previously reported, Bernstein analyst Aaron Gal downgraded Shire (SHPG) to Market Perform from Outperform. The analyst notes that he current controversy on Shire is the risk/reward into the closing of the Takeda (TKPYY) acquisition, and over the past few weeks deal spread narrowed, and the fundamentals have gotten a bit tougher in ADHD, HAE and Hemophilia.
09/04/18
BERN
09/04/18
DOWNGRADE
BERN
Market Perform
Shire downgraded to Market Perform from Outperform at Bernstein
05/09/18
LEER
05/09/18
NO CHANGE
LEER
Takeda/Shire transaction shows path for consolidation, says Leerink
Leerink analyst Geoffrey Porges notes that Takeda (TKPYY) confirmed its intention and agreement to purchase Shire (SHPG) for $62B in cash and stock. For the broader biopharma industry, the analyst believes Takeda's ability to lever up to an estimated 5.4x net debt/EBITDA suggests that investors are underestimating the ability of large cap biopharma companies to pursue large transactions. Nearly all of the large cap biopharma companies face looming growth issues or suffer under revenue-concentration risk discounts that could be mitigated by large-scale acquisitions, he contends. Porges believes that if Takeda can execute the Shire acquisition while checking the boxes of investor demands of a net positive ROIC, instant EPS accretion, maintaining an investment grade credit rating, and massive synergy savings, then others in the biopharma industry with stronger balance sheets and larger valuations can contemplate transactions that are substantially larger even than Shire.
GERN Geron
$1.69

0.02 (1.20%)

10/02/18
RILY
10/02/18
DOWNGRADE
Target $1.5
RILY
Neutral
Geron downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico downgraded Geron to Neutral and lowered his price target for the shares to $1.50 from $5.75. The analyst revised his outlook for imetelstat after Jannsen ended its collaboration with the company.
07/05/18
RILY
07/05/18
INITIATION
Target $5.75
RILY
Buy
Geron initiated with a Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico started Geron with a Buy rating and $5.75 price target.
03/19/18
PIPR
03/19/18
NO CHANGE
Target $7
PIPR
Overweight
Geron price target raised to $7 from $5 at Piper Jaffray
Piper Jaffray analyst Charles Duncan raised his price target for Geron to $7 after the company this morning reported year-end 2017 cash of $109M and provided an update on its IMerge and IMbark studies. The analyst projects the current cash will fund Geron's operations into 2020. He's encouraged by the update on the IMbark study in myelofibrosis and reiterates an Overweight rating on the shares.
CX Cemex
$6.23

0.145 (2.38%)

09/04/18
SBSH
09/04/18
NO CHANGE
Target $9.5
SBSH
Buy
Cemex worth $15 per share on asset-based valuation, says Citi
Citi analyst Dan McGoey, while continuing to favor a cash flow valuation analysis, says an asset-based valuation points to shares of Cemex being worth $15. The analyst estimates the gross value of Cemex's cement operations at $26B, the concrete division at $4B, Aggregates division at $1.7B, land and marine distribution terminals at $2B and its equity investments at $700M. The stock remains attractively valued under traditional multiples as well, McGoey tells investors in a research note. He keeps a Buy rating on Cemex with a price target of $9.50.
08/16/18
08/16/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Hold from Buy at Jefferies with analyst Ian Hilliker citing valuation following the stock's outperformance since he upgraded it in March. 2. Cemex (CX) downgraded to Hold from Buy at HSBC with analyst Eduardo Altamirano saying Cemex's deleveraging remains intact, but the pace at which debt is converted to equity is slowing down due to weaker than expected pricing and volumes in most regions, combined with higher input costs. 3. Cenovus Energy (CVE) downgraded to Hold from Buy at Canaccord with analyst Dennis Fong saying cash flow valuation is in line versus the large-cap group, which he thinks is appropriate given the company's above-average heavy oil exposure, moderated production growth profile, and higher leverage. 4. Nanometrics (NANO) downgraded to Neutral from Buy at DA Davidson with analyst Thomas Diffely saying that after outperforming its peer group over the past few years, the stock now trades at a 40% premium to its peers. 5. Coty (COTY) downgraded to Underperform from Buy at BofA/Merrill with analyst Olivia Tong citing inconsistent execution and increasing disruption across the mass beauty segment. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/16/18
08/16/18
DOWNGRADE
Target $9

Hold
Cemex downgraded to Hold at HSBC
As previously reported, HSBC downgraded Cemex to Hold from Buy and lowered its price target to $7.70 from $9. Analyst Eduardo Altamirano said Cemex's deleveraging remains intact, but the pace at which debt is converted to equity is slowing down due to weaker than expected pricing and volumes in most regions, combined with higher input costs. Altamirano now sees near-term free cash flow equal for both equity and debt holders, limiting upside for equity holders.
08/16/18
HSBC
08/16/18
DOWNGRADE
HSBC
Hold
Cemex downgraded to Hold from Buy at HSBC

TODAY'S FREE FLY STORIES

IRM

Iron Mountain

$32.64

-0.135 (-0.41%)

12:35
10/16/19
10/16
12:35
10/16/19
12:35
Options
Iron Mountain put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 12

    Nov

AMZN

Amazon.com

$1,776.00

7.3 (0.41%)

12:33
10/16/19
10/16
12:33
10/16/19
12:33
Hot Stocks
U.K.'s CMA announces formal investigation of Amazon's Deliveroo investment »

The Competition and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 21

    Nov

NBEV

New Age Beverages

$2.73

(0.00%)

12:32
10/16/19
10/16
12:32
10/16/19
12:32
Hot Stocks
New Age Beverages says on Twitter that 'big news coming' for Nestea »

The official Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:30
10/16/19
10/16
12:30
10/16/19
12:30
General news
FX Action: USD-JPY »

FX Action: USD-JPY topped…

NWL

Newell Brands

$19.31

0.14 (0.73%)

12:25
10/16/19
10/16
12:25
10/16/19
12:25
Options
Newell Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.04

0.77 (2.12%)

12:18
10/16/19
10/16
12:18
10/16/19
12:18
Hot Stocks
General Motors confirms UAW's statement regarding proposed tentative agreement »

GM said in a statement:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
10/16/19
10/16
12:17
10/16/19
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
10/16/19
10/16
12:16
10/16/19
12:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLAN

Anaplan

$44.40

-3.33 (-6.98%)

12:15
10/16/19
10/16
12:15
10/16/19
12:15
Options
Anaplan put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 17

    Oct

MCK

McKesson

$146.86

8.69 (6.29%)

, ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

12:11
10/16/19
10/16
12:11
10/16/19
12:11
On The Fly
Fly Intel: Wall Street's top stories at midday »

Stocks continue in a…

MCK

McKesson

$146.86

8.69 (6.29%)

ABC

AmerisourceBergen

$87.62

4.44 (5.34%)

CAH

Cardinal Health

$49.76

1.83 (3.82%)

JNJ

Johnson & Johnson

$136.44

3.6 (2.71%)

TEVA

Teva

$7.33

0.37 (5.32%)

GM

General Motors

$37.14

0.87 (2.40%)

UAL

United Airlines

$90.00

2.1 (2.39%)

BA

Boeing

$376.35

5.36 (1.44%)

BAC

Bank of America

$30.38

0.64 (2.15%)

MGM

MGM Resorts

$27.47

-0.4 (-1.44%)

BX

Blackstone

$46.86

-0.24 (-0.51%)

ACHN

Achillion

$6.25

2.595 (71.00%)

ALXN

Alexion

$102.60

-2.245 (-2.14%)

SFIX

Stitch Fix

$22.00

1.17 (5.62%)

WDAY

Workday

$158.51

-22.33 (-12.35%)

SNBR

Sleep Number

$45.49

-1.2 (-2.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 16

    Oct

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 12

    Nov

  • 12

    Nov

WB

Weibo

$52.17

2.85 (5.78%)

12:05
10/16/19
10/16
12:05
10/16/19
12:05
Options
Weibo call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APHA

Aphria

$5.00

-0.41 (-7.58%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Aphria falls -8.1% »

Aphria is down -8.1%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

NOW

ServiceNow

$251.40

-23.2 (-8.45%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
ServiceNow falls -8.3% »

ServiceNow is down -8.3%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Dec

AVD

American Vanguard

$13.39

-1.87 (-12.25%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
American Vanguard falls -12.6% »

American Vanguard is down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

  • 19

    Nov

  • 20

    Nov

HOV

Hovnanian

$28.26

2.2 (8.44%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Hovnanian rises 8.2% »

Hovnanian is up 8.2%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OMI

Owens & Minor

$6.98

0.55 (8.55%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Owens & Minor rises 8.2% »

Owens & Minor is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FIT

Fitbit

$3.75

0.305 (8.85%)

12:00
10/16/19
10/16
12:00
10/16/19
12:00
Hot Stocks
Fitbit rises 8.7% »

Fitbit is up 8.7%, or 30c…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GM

General Motors

$37.17

0.9 (2.48%)

11:57
10/16/19
10/16
11:57
10/16/19
11:57
Hot Stocks
UAW sends proposed tentative deal to UAW GM members to ratify »

Following five weeks of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PDCO

Patterson Companies

$17.42

0.09 (0.52%)

, HSIC

Henry Schein

$62.68

0.83 (1.34%)

11:55
10/16/19
10/16
11:55
10/16/19
11:55
Hot Stocks
Judge rules Patterson Companies violated U.S. antitrust laws in FTC complaint »

Chief Administrative Law…

PDCO

Patterson Companies

$17.42

0.09 (0.52%)

HSIC

Henry Schein

$62.68

0.83 (1.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

HSIC

Henry Schein

$62.41

0.56 (0.91%)

11:50
10/16/19
10/16
11:50
10/16/19
11:50
Hot Stocks
Judge dismisses FTC complaint against Henry Schein »

Chief Administrative Law…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 12

    Dec

XLF

Financial Select Sector

$28.06

-0.02 (-0.07%)

11:50
10/16/19
10/16
11:50
10/16/19
11:50
Options
Upside call buyer in Financial Sector ETF tied to hedge »

Upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRBT

iRobot

$58.37

0.58 (1.00%)

11:48
10/16/19
10/16
11:48
10/16/19
11:48
Hot Stocks
SharkNinja says 'will aggressively defend' against iRobot patent suit »

SharkNinja announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

RNET

RigNet

11:46
10/16/19
10/16
11:46
10/16/19
11:46
Initiation
RigNet initiated  »

RigNet initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATNI

ATN International

11:46
10/16/19
10/16
11:46
10/16/19
11:46
Initiation
ATN International initiated  »

ATN International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

AGYS

Agilysys

$25.64

-0.67 (-2.55%)

11:46
10/16/19
10/16
11:46
10/16/19
11:46
Initiation
Agilysys initiated  »

Agilysys initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.